Harry F. Bisel

1.6k total citations
38 papers, 1.3k citations indexed

About

Harry F. Bisel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Harry F. Bisel has authored 38 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 13 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Harry F. Bisel's work include Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (9 papers) and Chemotherapy-induced cardiotoxicity and mitigation (7 papers). Harry F. Bisel is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (9 papers) and Chemotherapy-induced cardiotoxicity and mitigation (7 papers). Harry F. Bisel collaborates with scholars based in United States, Cyprus and Mexico. Harry F. Bisel's co-authors include David L. Ahmann, Richard G. Hahn, John H. Edmonson, Edward T. Creagan, James N. Ingle, Stephen Frytak, R. G. Hahn, William L. Wilson, Stephanie Green and Larry K. Kvols and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Harry F. Bisel

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harry F. Bisel United States 18 676 391 320 317 222 38 1.3k
Reginald P. Pugh United States 19 581 0.9× 221 0.6× 269 0.8× 177 0.6× 217 1.0× 34 1.1k
Verena Hug United States 16 767 1.1× 688 1.8× 186 0.6× 262 0.8× 234 1.1× 44 1.4k
Hwee‐Yong Yap United States 18 765 1.1× 174 0.4× 398 1.2× 97 0.3× 204 0.9× 31 1.3k
Cecilia Nisticò Italy 23 1.2k 1.8× 555 1.4× 403 1.3× 228 0.7× 306 1.4× 70 1.6k
Massimo Lopez Italy 21 1.6k 2.4× 516 1.3× 598 1.9× 207 0.7× 405 1.8× 59 2.2k
John F. Sandbach United States 15 1.5k 2.2× 864 2.2× 360 1.1× 413 1.3× 661 3.0× 32 2.4k
A. Farris Italy 23 949 1.4× 599 1.5× 408 1.3× 353 1.1× 287 1.3× 81 1.6k
A Mangalik United States 10 917 1.4× 422 1.1× 368 1.1× 603 1.9× 203 0.9× 32 1.4k
Per‐Ebbe Jönsson Sweden 20 927 1.4× 270 0.7× 434 1.4× 115 0.4× 239 1.1× 35 1.5k
H. C. Falkson South Africa 16 608 0.9× 349 0.9× 199 0.6× 256 0.8× 174 0.8× 32 1.0k

Countries citing papers authored by Harry F. Bisel

Since Specialization
Citations

This map shows the geographic impact of Harry F. Bisel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry F. Bisel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry F. Bisel more than expected).

Fields of papers citing papers by Harry F. Bisel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry F. Bisel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry F. Bisel. The network helps show where Harry F. Bisel may publish in the future.

Co-authorship network of co-authors of Harry F. Bisel

This figure shows the co-authorship network connecting the top 25 collaborators of Harry F. Bisel. A scholar is included among the top collaborators of Harry F. Bisel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry F. Bisel. Harry F. Bisel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahmann, David L., Daniel J. Schaid, James N. Ingle, et al.. (1991). A Randomized Trial of Cyclophosphamide, Doxorubicin, and Prednisone Versus Cyclophosphamide, 5-Fluorouracil, and Prednisone in Patients with Metastatic Breast Cancer. American Journal of Clinical Oncology. 14(3). 179–183. 8 indexed citations
2.
Ahmann, David L., Edward T. Creagan, Richard G. Hahn, et al.. (1989). Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer. 63(2). 224–227. 77 indexed citations
3.
Ahmann, David L., Daniel J. Schaid, Harry F. Bisel, et al.. (1987). The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug.. Journal of Clinical Oncology. 5(12). 1928–1932. 53 indexed citations
4.
Ingle, James N., James E. Krook, Lloyd K. Everson, et al.. (1986). Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer.. Journal of Clinical Oncology. 4(2). 178–185. 121 indexed citations
5.
Ahmann, David L., Judith R. OʼFallon, Paul W. Scanlon, et al.. (1982). A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy. American Journal of Clinical Oncology. 5(4). 371–382. 69 indexed citations
6.
Bisel, Harry F.. (1980). Management of locally advanced and disseminated breast cancer—chemotherapy. Cancer. 46(S4). 1079–1083. 2 indexed citations
7.
Ingle, J. N., David L. Ahmann, Judith R. OʼFallon, et al.. (1980). Randomized phase II trial of rubidazone and adriamycin in women with advanced breast cancer.. PubMed. 63(11-12). 1701–5. 9 indexed citations
8.
Creagan, Edward T., R. G. Hahn, David L. Ahmann, & Harry F. Bisel. (1977). A Clinical Trial Adriamycin (NSC 123127) in Advanced Sarcomas. Oncology. 34(2). 90–91. 30 indexed citations
9.
Ahmann, David L., R. G. Hahn, Harry F. Bisel, Robert T. Eagan, & J H Edmonson. (1975). Comparative study of methyl-CCNU (NSC-95441) with cyclophosphamide (NSC-26271) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) with vincristine (NSC-67574) in patients with disseminated malignant melanoma.. PubMed. 59(2 Pt 1). 451–3. 3 indexed citations
10.
11.
Ahmann, David L., Charles G. Moertel, Harry F. Bisel, et al.. (1974). A Controlled Evaluation of 5-Fluorouracil Utilizing a Single Injection Technique. Oncology. 29(2). 166–171. 2 indexed citations
12.
Talley, Robert W., et al.. (1973). A dose-response evaluation of androgens in the treatment of metastatic breast cancer. Cancer. 32(2). 315–320. 13 indexed citations
13.
Ahmann, David L., Richard G. Hahn, & Harry F. Bisel. (1972). A comparative study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) and imidazole carboxamide (NSC 45388) with vincristine (NSC 67574) in the palliation of disseminated malignant melanoma.. PubMed. 32(11). 2432–4. 15 indexed citations
14.
Bisel, Harry F.. (1971). Cancer: Diagnosis, Treatment, & Prognosis. Archives of Dermatology. 103(5). 571–571. 2 indexed citations
15.
Wilson, William L., et al.. (1970). Prolonged low-dosage administration of hexamethylmelamine (NC 13875). Cancer. 25(3). 568–570. 46 indexed citations
16.
Bisel, Harry F., et al.. (1970). Clinical studies with tubercidin administered by direct intravenous injection.. PubMed. 30(1). 76–8. 31 indexed citations
17.
Wilson, William L., et al.. (1969). Phase II study of hexamethylmelamine (NSC 13875). Cancer. 23(1). 132–136. 41 indexed citations
18.
Volk, Herbert, et al.. (1965). Antitumor efficacy of norandrolone phenpropionate compared with testosterone propionate in advanced breast cancer. Cancer. 18(5). 651–655. 1 indexed citations
19.
Hulka, J.F. & Harry F. Bisel. (1965). Combined intra-arterial chemotherapy and radiation treatment for advanced cervical carcinoma. American Journal of Obstetrics and Gynecology. 91(4). 486–490. 8 indexed citations
20.
Bisel, Harry F.. (1953). INCIDENCE AND CLINICAL MANIFESTATIONS OF CARDIAC METASTASES. Journal of the American Medical Association. 153(8). 712–712. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reginald P. Pugh Breakdown of academic impact, for papers by Verena Hug Breakdown of academic impact, for papers by Hwee‐Yong Yap Breakdown of academic impact, for papers by Cecilia Nisticò Breakdown of academic impact, for papers by Massimo Lopez Breakdown of academic impact, for papers by John F. Sandbach Breakdown of academic impact, for papers by A. Farris Breakdown of academic impact, for papers by A Mangalik Breakdown of academic impact, for papers by Per‐Ebbe Jönsson Breakdown of academic impact, for papers by H. C. Falkson
Rankless by CCL
2026